Published in J Heart Lung Transplant on February 06, 1992
Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci (2001) 1.89
High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol (2000) 1.24
Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg (1992) 1.18
Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma (2008) 1.16
Lung transplantation. Part II. Postoperative management and results. West J Med (1997) 1.06
Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci (1994) 1.06
A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg (1993) 1.00
Pediatric lung transplantation. The years 1985 to 1992 and the clinical trial of FK 506. J Thorac Cardiovasc Surg (1993) 0.96
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation (2008) 0.95
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. J Clin Oncol (2012) 0.87
Clinicopathologic implications of Epstein-Barr virus related B cell lymphoma in immunocompromised patients. J Clin Pathol (1995) 0.84
Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II. Dig Dis Sci (2008) 0.84
Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol (2014) 0.80
Posttransplant lymphoproliferative disease after lung transplantation. Clin Dev Immunol (2013) 0.80
Post heart/lung transplantation management. J R Soc Med (1995) 0.78
Two cases of post transplant lymphoproliferative disorder in lung transplant recipients. Korean J Intern Med (2004) 0.78
Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer (2006) 0.78
Epstein-Barr virus-associated pneumonia and bronchiolitis obliterans syndrome in a lung transplant recipient. Med Microbiol Immunol (2010) 0.77
Post-transplantation lymphoproliferative disorder in living-donor liver transplantation: a single-center experience. Surg Today (2012) 0.77
Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med (2015) 0.76
Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation. Thorax (1995) 0.76
Contrast-enhanced ultrasound findings of post-transplant lymphoproliferative disorder in a transplanted kidney: A case report and literature review. J Radiol Case Rep (2015) 0.75
Management of cystic fibrosis before and after lung transplantation. J R Soc Med (1997) 0.75
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation (1983) 3.60
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis (1988) 2.76
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
Lessons learned in pediatric heart transplantation. Ann Thorac Surg (1989) 2.46
Cognitive outcome after coronary artery bypass: a one-year prospective study. Ann Thorac Surg (1997) 2.23
Cardiac transplantation with cyclosporin A and prednisone. Ann Surg (1982) 2.21
Alternative approach to multivessel coronary disease with integrated coronary revascularization. J Thorac Cardiovasc Surg (1999) 2.08
Blood usage in lung transplantation. Transfusion (1998) 2.06
Absent right superior vena cava with persistent left superior vena cava: implications and management. Am J Cardiol (1980) 1.94
Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg (1995) 1.92
Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation (2001) 1.91
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis (1985) 1.88
HeartMate II left ventricular assist system: from concept to first clinical use. Ann Thorac Surg (2001) 1.82
Minimally invasive coronary artery bypass grafting. Ann Thorac Surg (1996) 1.81
Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation (2000) 1.76
Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation (2001) 1.74
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation (1987) 1.71
Early Function of Heart, Liver, and Kidney Allografts Following Combined Procurement. Transplant Proc (1984) 1.66
Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65
Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol (1989) 1.65
Traumatic aortic rupture: diagnosis and management. Ann Thorac Surg (1998) 1.64
Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant (1999) 1.63
Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med (1992) 1.58
Acute myocarditis. Rapid diagnosis by PCR in children. Circulation (1994) 1.58
Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years. J Pediatr (1997) 1.57
Principles of multiple organ procurement from cadaver donors. Ann Surg (1983) 1.56
Valvular disease in the elderly: influence on surgical results. Ann Thorac Surg (1993) 1.55
Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg (1995) 1.54
Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology (2000) 1.54
Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum. Arch Intern Med (1987) 1.53
Optimal perioperative immunosuppression in cardiac transplantation using rabbit antithymocyte globulin. Transplantation (1990) 1.52
Morphological monitoring of human small bowel allografts. Transplant Proc (1993) 1.52
Large airway inflammation in heart-lung transplant recipients--its significance and prognostic implications. Transplantation (1990) 1.51
Organ procurement for pulmonary transplantation. Ann Thorac Surg (1989) 1.49
Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurement. Am J Transplant (2014) 1.48
Regional low-flow perfusion provides cerebral circulatory support during neonatal aortic arch reconstruction. J Thorac Cardiovasc Surg (2000) 1.48
Anastomotic pitfalls in lung transplantation. J Thorac Cardiovasc Surg (1994) 1.47
Single- versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg (1998) 1.46
Preoperative and postoperative comparison of patients with univentricular and biventricular support with the thoratec ventricular assist device as a bridge to cardiac transplantation. J Thorac Cardiovasc Surg (1997) 1.46
Endobronchial management of benign, malignant, and lung transplantation airway stenoses. Ann Thorac Surg (1995) 1.45
Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant (1992) 1.45
Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit. J Heart Lung Transplant (1994) 1.43
Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis (1985) 1.43
Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge. Am J Med (1989) 1.42
Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology (1996) 1.42
Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg (1998) 1.41
Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant (2009) 1.41
Proteins of the respiratory tract after heart-lung transplantation. Transplantation (1989) 1.40
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
Predicting ICU length of stay following single lung transplantation. Chest (1996) 1.40
Cardiopulmonary bypass as an adjunct to pulmonary surgery. Chest (1996) 1.40
Prediction of mortality in patients awaiting cardiac transplantation: increased risk of sudden death in ischemic compared to idiopathic dilated cardiomyopathy. Isr J Med Sci (1996) 1.40